Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies
GlaxoSmithKline has joined other drugmakers in halting new clinical trials in Russia while still providing essential medicines to the country. Like others in the sector, it will push on with existing trials.
It said it would not start any new clinical trials and would not enrol new patients into existing trials in Russia, echoing steps taken by its British rival AstraZeneca and the US firms Pfizer and Eli Lilly. GSK has already stopped advertising its products in the country and will donate any profits made there to humanitarian relief efforts.
